With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

On Friday, Novo Nordisk announced that the U.S. Food and Drug Administration (FDA) had approved Wegovy for the treatment of ...

Market Position and Recent Performance Novo Nordisk has a market capitalization of $176 billion, and its stock is currently priced at $54.43, reflecting a significant change of 5.03% today. Over the ...

Novo Nordisk A/S (NYSE:NVO) has made headlines recently by reporting an impressive 18% sales growth in the first half of 2025. This growth highlights the company's significant role in the global ...

The string of negative updates from Novo Nordisk and positive news flow from the main competitor Eli Lilly has finally ended ...

Novo Nordisk (NYSE: NVO) first earned U.S. approval for its now-famous weight management medicine Wegovy in June 2021. That marked the beginning of a strong run for the company on the stock market.

Eli Lilly is a leader in the market for GLP-1 medicines. The company's Zepbound, indicated for weight loss, is racking up ...

Novo Nordisk A/S (NYSE:NVO) is one of the Reddit Stocks with the Highest Upside Potential. On August 6, the company stated ...

Novo Nordisks stock has tumbled from record highs after slashing its 2025 outlook, as fierce competition, leadership changes, ...

Novo Nordisk has plummeted back to Earth after a stunning rise driven by Ozempic and Wegovy. Can the storied Danish pharma ...

More than one in five UK adults tried to access weight-loss medications in the past year alone, according to a survey by the ...

Here are five oral obesity candidates that, according to Mizuho’s Graig Suvannavejh, could change the weight loss game.